Voisin Consulting Life Sciences (VCLS) is a team of more than 200 life sciences professionals, committed to delivering innovative therapies to patients. We believe that product development must be driven by a solid understanding of the environment within which the product will be launched, and the criteria by which elements of the development will be assessed by both regulators and payers. We start from science and medical needs, as we collaborate with our clients’ teams to drive innovative products along development and commercialization.
From discovery to patients, our team of healthtech product specialists offers integrated solutions to development planning, manufacturing, quality and control, nonclinical and clinical testing, safety monitoring, and interactions with regulators and payers.
Our Mission
Voisin Consulting Life Sciences is the global reference partner to expedite access of HealthTech products to regulated markets.
Our vision
Science transforms lives, we successfully partner with innovative pharma biotech and device developers for the benefit of patients.
Our Values
People
We empower individuals and teams and provide them with an environment to grow and succeed.
We treat others as we would like to be treated with trust, respect and fairness.
We recognize effort and reward success.
Innovation
We dare to think out of the box and disrupt the status quo.
We challenge everything in due time, we accept challenge and the right to fail.
In an uncertain, ambiguous and complex world, we move and change with agility.
Passion
We work with energy and enthusiasm and we have fun.
We take ownership of our tasks, projects and missions.
We promote the synergy of teamwork.
Excellence
We consistently do our best to understand and satisfy the needs of our partners, clients and colleagues.
We bring true added value, discerning the necessary from the superfluous.
We strive to make tomorrow better than today by continuous improvement and learning.
Our Story
1997
Dr. Emmanuelle Voisin founded VCLS to offer a tailored service for emerging biotech companies
2000
VCLS clients’ were among the first four to obtain ODD in Europe (2000 was the year when EU orphan regulation came into force)
2002
Among the first four to obtain MAA in orphan indication for which the ODD granted in 2000
2003
Launched Clinical Trial Operation service
2005
Expanded to the US market with an office in Cambridge, US2007
First to obtain MAA under Accelerated Approval Program (AAP)
2008
Launched services for Medical Device
2009
First to obtain MAA in ATMP
2014
Won International Regulatory Excellence Awards from TOPRA
2017
Inauguration of VCLS innovation center – Neighborhood, dedicated to start-ups.
2019
Dr. Emmanuelle Voisin leads the In Silico Policy Working Group at Avicenna Alliance International Working Group
2019
Expanded its capabilities in Northern Europe with the acquisition of IWA Consulting
2020
Partnered with its spin-off iliomad to develop GDPR services and digital tools to help maintain the confidentiality of private health information while allowing for the exchange of data sets among various stakeholders.
2021
Acquisition of Quanta Medical, a privately-held company focusing on designing, implementing and reporting clinical studies with proprietary digital tools for the healthcare industry.
About 
Join Us 
